Novartis acquires Vedere Bio
Novartis has acquired Vedere Bio and added a platform for adeno-associated virus-based gene therapy delivery, according to a press release.
The acquisition includes two preclinical optogenetic AAV gene therapy programs for treating inherited retinal dystrophies and geographic atrophy, and technologies such as light-sensing proteins that can be be delivered to retinal cells as well as AAV delivery vectors that enable intravitreal injection treatment, the release said.
“We believe that gene therapy technologies have transformative potential for treating blinding diseases,” Cynthia Grosskreutz, global head of ophthalmology, Novartis Institutes for BioMedical Research, said in the release. “With the new tools that this acquisition brings to the table, we will no longer be limited to replacing single genetic mutations that are causing eye diseases.”
The acquisition price was not disclosed in the release.
Read more about